Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the ...

Most U.S. stocks fell after a report said inflation is unexpectedly worsening for Americans. The S&P 500 dropped 0.3% ...

Shares of Super Micro Computer jumped after the company set a sales outlook for fiscal 2026 that blows past current Wall Street forecasts, unwinding a selloff earlier in the day.

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV products.

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed ... oral option could complement other new products designed to improve compliance with ART ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.